Eli Lilly, the manufacturer of Mounjaro, has significantly increased the wholesale price of the medication across the UK. This change affects all healthcare providers and may impact how each chooses to price treatment moving forward. For many, it raises concerns about long-term affordability and access to treatment.
Mounjaro (tirzepatide) remains a clinically proven, effective weight loss treatment. However, rising costs are prompting many to explore alternatives particularly Wegovy (semaglutide), which is now more cost-effective.
What the Mounjaro price hike means for patients: Expert insight
What's changed with Mounjaro pricing?
The cost of Mounjaro has increased across the UK, affecting all providers. Each provider may respond differently, with some adjusting prices for everyone, others making changes more selectively.
It’s important to note that:
- Mounjaro remains a safe, effective and trusted treatment. It is absolutely fine if you choose to continue with your current medication.
- This decision comes from the manufacturer: The price rise originates with Eli Lilly, not providers.
What’s driving the price increase?
Eli Lilly says it will increase the UK list price for Mounjaro from 1st September so it is more in line with other developed countries. When Mounjaro launched in the UK, the price was set lower to help patients get access quickly. Lilly now says newer evidence and market changes support bringing the UK price into line. Clinics and pharmacies buy the medicine from wholesalers, so when the list price changes, the price patients pay can change too.
You can read Eli Lilly’s press release here.
What this means for patients
This price change affects all UK providers and therefore, every UK patient prescribed Mounjaro, whether through a pharmacy, private clinic, or digital provider like Voy.
Our commitment to you
At Voy, we understand how disruptive sudden price increases can be. We want your journey to stay as smooth, accessible, and affordable as possible, so we have absorbed as much of the increase as we can. For our existing patients, this means keeping your price as close as possible to what you are used to. However, if you are comparing options on cost, Wegovy is currently the most cost effective GLP-1 at Voy.
New to Voy
You will see the updated prices at checkout. You can find more information here.
Existing Voy customers
If you’re already with Voy, your plan will move to our existing-customer Mounjaro prices. These are lower than the prices new patients will pay, because we’ve chosen to absorb more of the recent price rise on your behalf.
Your options
1. Stay on Mounjaro at your current dose
You can continue treatment. Your monthly price will reflect the updated existing-customer rate.
2. Switch to Wegovy
If you choose to switch and are clinically suitable, Wegovy is currently the most cost effective GLP-1 option at Voy. Longer 3 and 6 month plans are available to reduce the monthly price. Where eligible, a £50 switch credit may be applied when moving from Mounjaro to Wegovy for existing customers.
If you’re concerned about cost or considering switching, you can transition to Wegovy through our clinician-guided switching pathway, with tailored support to help you continue your progress without interruption.
3. Consider a dose reduction on Mounjaro
If you prefer to remain on Mounjaro but manage cost, discuss stepping down a dose with your clinician. For some patients this keeps the monthly price closer to what they pay now. Any change should be guided by your prescriber.
Why Wegovy is now the go-to alternative
We know an unexpected cost increase can make continued treatment difficult. That’s why many patients are now switching to Wegovy, a clinically proven alternative that is currently more affordable for most UK patients. But it’s not just about cost, Wegovy has several compelling advantages:
- Comparable Weight Loss Results: Wegovy 7.2mg (expected in the UK later this year) demonstrated an average weight loss of 20.7% in the STEP-UP trial. One in three participants lost 25% or more of their body weight. These are results that narrow the gap with higher-dose Mounjaro.
- Cardiovascular benefits: Wegovy is currently the only GLP-1 medication licensed in the UK to reduce the risk of major cardiac events, including heart attack and stroke, in people with obesity and established heart disease, based on the results from the SELECT CVOT trial. While recent trial results suggest that Mounjaro offers similar cardiovascular protection, it is not yet approved for this indication in the UK.
- Affordability: With Eli Lilly’s price increase, Wegovy has become the more accessible option for many. At Voy, our longer, more affordable plans are designed to support consistent treatment and better long-term outcomes.
Want a side-by-side view of results, dosing and side effects? Read our Mounjaro vs Wegovy comparison.
How switching works at Voy
Switching from Mounjaro to Wegovy isn’t about starting over, it’s about continuing your progress safely and confidently. At Voy, we’ll recommend the most appropriate starting dose for you, guided by the best available clinical data and your individual treatment history.
Here’s how it works:
- If you’ve tolerated Mounjaro well, we may suggest a higher starting dose of Wegovy. This helps maintain momentum and avoid unnecessary plateaus or regressions.
- If you’ve had side effects (like nausea, bloating, or digestive discomfort), we may recommend a more gradual starting dose when switching. This helps your body adjust and reduces the risk of symptoms coming back.
- Your starting dose is tailored to you. We look at your clinical history, how long you’ve been on treatment, your last dose, side effect history, and how you’ve responded, not just a standard protocol.
- You’ll still increase your dose every 4 weeks, just as with Mounjaro, until you reach your optimal dose which is the one that consistently manages appetite and supports weight loss.
Beginning Wegovy at a slightly higher dose is considered “off-label,” as the standard guidance is to always start from the lowest dose. For people switching from Mounjaro however, we recognise this may not be the most clinically appropriate approach. At Voy, we take your individual treatment history and the best available evidence into account to recommend the dose that will help you continue your progress safely and effectively. Learn more about off-label prescribing.
Considering a switch?
We don’t just switch your medication, we support your entire transition. Here’s what makes the Voy switch process different:
- Comprehensive treatment review - We look at your full Mounjaro journey, including your dose, tolerance, and weight loss progress, to make sure you don’t lose momentum during the switch.
- Flexible dose options - Whether you need a slower start or a higher dose of Wegovy to maintain progress, our clinicians recommend the safest, most effective starting point based on your personal data.
- Clinician-approved plans - Every switch is reviewed by a qualified clinician. You'll complete a short medical questionnaire and can speak to a clinician directly via our hotline or live chat within minutes.
- In-app tools and tracking - Stay on track with injection reminders, weight and appetite logging, and direct messaging with our team—plus access to expert-led videos, tips, and support.
- Ongoing personalised coaching - Beyond the prescription, we offer 1-to-1 support on nutrition, behaviour change, and lifestyle to help you get the best results long term.
If you decide to switch, you can rely on us to make the process smooth, safe, and fully supported from start to finish.
*Please note, in order to benefit from our price freeze, your next order must be on or before 14th September.
¹
